Transarterial infusion chemotherapy combined with lenvatinib and tislelizumab versus intravenous chemotherapy for unresectable pancreatic ductal adenocarcinoma: a retrospective propensity score matching analysis
Frontiers in Oncology · 19.08.2026 · 16
DOI: 10.3389/fonc.2026.1898332 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 19.08.2026. Verfasst von Haohao Lu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies with dismal prognosis for unresectable cases. Systemic chemotherapy shows limited efficacy, while transarterial infusion chemotherapy (HAIC) enables targeted drug delivery, and the combination of anti-angiogenic agents and immune checkpoint inhibitors has demonstrated synergistic effects in solid tumors.
Methods
In this retrospective, single-center propensity score-matched study, 183 unresectable PDAC patients treated between January 2021 and December 2024 were analyzed Propensity score matching (PSM) was performed at a 1:1 ratio, resulting in 45 patients in the HAIC + lenvatinib + tislelizumab group and 45 patients in the intravenous chemotherapy group. The primary endpoints were overall survival (OS) and progression-free survival (PFS); secondary endpoints included objective response rate (ORR), disease control rate (DCR), and safety.
Results
After PSM, baseline characteristics were well-balanced.1). The HAIC + lenvatinib + tislelizumab group achieved significantly higher ORR (37.8% vs. 17.8%, P = 0.023) and DCR (88.9% vs. 64.4%, P = 0.004) than the chemotherapy group. Median OS was 13.1 months (95% CI: 11.4–14.7) in the experimental group versus 8.8 months (95% CI: 7.1–10.9) in the control group (P<0.001). Median PFS was 6.0 months (95% CI: 5.0–6.9) versus 3.7 months (95% CI: 1.9–4.0), respectively (P<0.001). The most common grade ≥3 adverse events were hypertension (15.6% vs. 2.2%, P = 0.012) in the HAIC + lenvatinib + tislelizumab group and neutropenia (24.4% vs. 6.7%, P = 0.008) in the chemotherapy group.
Conclusions
HAIC combined with lenvatinib and tislelizumab significantly was associated with significantly prolonged survival and improved tumor response in unresectable PDAC with manageable toxicity, providing a promising therapeutic strategy for this devastating disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China.
- Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, China.
Zitieren
APA
Lu, H., Liang, B., Fu, Q., & Xia, X. (2026). Transarterial infusion chemotherapy combined with lenvatinib and tislelizumab versus intravenous chemotherapy for unresectable pancreatic ductal adenocarcinoma: a retrospective propensity score matching analysis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1898332
Vancouver
Lu H, Liang B, Fu Q, Xia X. Transarterial infusion chemotherapy combined with lenvatinib and tislelizumab versus intravenous chemotherapy for unresectable pancreatic ductal adenocarcinoma: a retrospective propensity score matching analysis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1898332
BibTeX
@article{Lu2026,
author = {Lu, Haohao and Liang, Bin and Fu, Qing and Xia, Xiangwen},
title = {Transarterial infusion chemotherapy combined with lenvatinib and tislelizumab versus intravenous chemotherapy for unresectable pancreatic ductal adenocarcinoma: a retrospective propensity score matching analysis},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1898332}
}
EUVIMED